In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in ...

The global macular degeneration treatment market is poised for significant growth, projected to expand from USD 9.1 billion ...

For people living with diabetes, vision complications require immediate attention. Diabetic macular edema (DME), a condition ...

Detailed price information for Adverum Biotechnologies Inc (ADVM-Q) from The Globe and Mail including charting and trades.

(GLOBE NEWSWIRE) --  (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ®), announced today that ...

The three trials were all testing an experimental once-monthly dosing regimen for Beovu, which is already approved for wet AMD as an injection ... as well as other anti-VEGF drugs have persistent ...

that gives patients an alternative to regular injections into the eye. Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered ...

In randomized phase III trials two anti-vascular endothelial growth factor (VEGF) approaches have yielded survival benefit in patients with metastatic cancer. In one approach, the addition of ...

including intravitreal injections of anti-VEGF drugs. The current status of these novel therapeutic agents is also discussed. The slit-lamp binocular macular biomicroscopy demonstrates that CNV ...

The company’s lead candidate, 4D-150 for wet AMD, has shown promising results in Phase 1/2 trials. Interim data demonstrated ...

After hours: November 22 at 4:48 PM EST Loading Chart for EYE ...